Hemispherx Biopharma Price / Sales Ratio: 334.18
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
HEB Price / Sales Ratio Rankings
| Overall | 0th percentile | 4360 of 4365 |
| Sector | 0th percentile | 456 of 457 in Healthcare |
| Industry | 0th percentile | 123 of 124 in Biotechnology |
HEB Price / Sales Ratio Range, Past 5 Years
| Minimum | 37.64 | Sep 2002 |
| Maximum | 354.09 | Dec 2001 |
| Average |
About Price to Sales Ratio
The price to sales ratio (PS ratio) is calculated by dividing stock price by the revenue per share. It is most useful for comparing companies within a sector or industry because "normal" values for this ratio vary from industry to industry. In general, low price to sales ratios are more appealing because they suggest that a company is undervalued.
An example illustrating why PS ratios should not be compared across industries: On June 21, 2010, Starbucks had a PS ratio of 1.12 while Yahoo! had a PS ratio of 2.56. In other words, Yahoo! shareholders were paying $2.56 for $1 of sales while Starbucks shareholders would only pay $1.12 for $1 of sales. However, at that same moment, the two companies' price to earnings ratios were virtually identical (Starbucks: 28.09 and Yahoo!: 27.78). Hence, shareholders were paying nearly the same amount for $1.00 in earnings. The PS ratios, though, are less comparable since Yahoo!'s profit margins are much higher than that of Starbucks.
Learn More
You may also be interested in these HEB related companies
HEB News
$HEB , I am early but bot it this morning. loking for a nice pop
about 9 days ago by 3DTRADINGTRADER
about 9 days ago by 3DTRADINGTRADER
UPDATE: Novavax, Hemispherx BioPharma, Biocryst Spiking Higher on H1N1 Reports in Mexico
Jan 23, 11:00AM Benzinga
Jan 23, 11:00AM Benzinga
Hemispherx Biopharma Receives U.S. Patent Office Notification of Two New Patents Granted for Alferon(R) LDO
Jan 17, 8:30AM GlobeNewswire
Jan 17, 8:30AM GlobeNewswire
Hemispherx Biopharma (HEB) Recieves FDA Extension for NDA for Treatment of Chronic Fatigue Syndrome
Jan 11, 8:35AM Street Insider
Jan 11, 8:35AM Street Insider
$HEB shares up 14% following extension to modify NDA for treatment of CFS
about 32 days ago by Street_Insider
about 32 days ago by Street_Insider
Hemispherx Biopharma (HEB) Gets Extension from FDA for CFS NDA Modification
Jan 11, 8:31AM Street Insider
Jan 11, 8:31AM Street Insider
FDA Grants $HEB Extension in Its Pending New Drug Application for the Treatment of Chronic Fatigue
about 32 days ago by Benzinga
about 32 days ago by Benzinga
What's up with $HEB !?!? Up 20% on more than 4X average daily volume.
about 69 days ago by swingtrades99
about 69 days ago by swingtrades99
Hemispherx Biopharma Announces Further Adjournment on Proposal Number 4 From the 2011 Annual Meeting of Stockholders
Nov 09, 4:13PM GlobeNewswire
Nov 09, 4:13PM GlobeNewswire
Hemispherx Biopharma Announces Financial Results for the Three Months Ended September 30, 2011
Nov 09, 12:26PM GlobeNewswire
Nov 09, 12:26PM GlobeNewswire
Hemispherx Biopharma, Inc. to Host Conference Call on Chronic Fatigue Syndrome Progress Thursday, October 27, 2011
Oct 24, 10:22AM GlobeNewswire
Oct 24, 10:22AM GlobeNewswire
Hemispherx Biopharma to Present at the Rodman and Renshaw 13th Annual Global Investment Conference
Sep 08, 4:30PM GlobeNewswire
Sep 08, 4:30PM GlobeNewswire
Hemispherx (HEB) Enters New Alferon N Injection Agreement with Armada Health Care
Sep 06, 8:40AM Street Insider
Sep 06, 8:40AM Street Insider
Hemispherx Biopharma Enters Into a Strategic Alliance With Armada Health Care for Alferon N Injection(R)
Sep 06, 8:30AM GlobeNewswire
Sep 06, 8:30AM GlobeNewswire
FDA authorizes new Hemispherx $HEB clinical trial of intranasal Ampligen(R); stock moving in pre-market
about 207 days ago by Street_Insider
about 207 days ago by Street_Insider
Hemispherx Biopharma Says FDA Lifts Hold On phase 2 Alferon Trial $heb
about 404 days ago by goldenchris
about 404 days ago by goldenchris
El CEO de $MCP me hace acordar al CEO delincuente de $HEB asi terminara.
about 409 days ago by sebatrader
about 409 days ago by sebatrader
Manuel Asensio has numerous SEC violations & should've stuck to SS: & reporting on Small Cap shams like $HEB. His $NFLX remarks = no value.
about 436 days ago by Legacy_Trades
about 436 days ago by Legacy_Trades
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| HEB | 0.37 | 0.04 | 10.45% | 50.13M |
| IPG | 10.73 | -0.08 | -0.74% | 5.13B |
| WFC | 30.26 | -0.32 | -1.05% | 159.58B |
| ALU | 2.19 | 0.25 | 12.89% | 4.96B |
| PHX | 28.86 | -1.24 | -4.12% | 238.38M |
| AGM | 20.40 | -0.54 | -2.58% | 211.14M |
| ATK | 58.27 | -0.29 | -0.50% | 1.92B |
| VZ | 37.69 | -0.23 | -0.61% | 106.70B |
| XOM | 83.80 | -1.08 | -1.27% | 401.67B |
| CVS | 43.18 | 0.18 | 0.42% | 56.20B |
